Adolescent ; Adult ; Child ; Female ; Humans ; Male ; Middle Aged ; Myringoplasty ; Risk Factors ; Tympanic Membrane Perforation ; etiology ; surgery ; Young Adult

OBJECTIVETo evaluate the curative effects of Betamethasone for treatment of voice hoarseness of chronic hypertrophic laryngitis.

METHODSFrom July, 2001 to December, 2002, 48 cases of the chronic hypertrophic laryngitis had been treated by injected of Betamethasone at vocal cords. Fundamental frequency (FO), jitter, shimmer, normalized noise energy (NNE) acoustics' parameters were tested and paired t test were calculated. The voice quality of 1 month and 6 months after treatment were synthetically graded, one-way ANOVA and the DANCAN test were conducted.

RESULTSEight cases were injected under surface anesthesia with indirect laryngoscopy at the clinic service. Thirty-eight cases were injected under general anesthesias with micro-laryngoscopes. After six months following up, the voice hoarseness was obviously improved, the congestion or oedema of vocal cord was lessened, and the voice quality was improved as well. The results of F0, jitter, shimmer, NNE acoustics' parameters after treatment 6 months showed: 8 of 48 cases (17.39%) had treatment effect, 22 out of 48 cases (47.83%) had obviously effect, 10 out of 48 cases (21.74%) had cured. The total effectiveness had reached 86.96% (40 of 48 cases). Six of 48 cases (13.04%) was failure.

CONCLUSIONVocal cord injection of Betamethasone for the hoarseness of chronic hypertrophic laryngitis is an effective treatment method.

Adult ; Betamethasone ; administration & dosage ; therapeutic use ; Chronic Disease ; Female ; Humans ; Injections, Intralesional ; Laryngitis ; therapy ; Male ; Treatment Outcome ; Vocal Cords ; Voice Quality

OBJECTIVETo investigate the risk factors for depressive disorders in manufacturing workers and to provide a basis for developing health promotion measures at workplace.

METHODSA questionnaire survey was performed in 8085 front-line production workers from 33 manufacturing enterprises in Nanhai District of Foshan, Guangdong Province, China. The questionnaire contained a survey of demographic characteristics, the Safety Climate Scale, the Center for Epidemiological Studies Depression Scale, etc. The multilevel logistic regression analysis was applied to investigate the risk factors for depressive disorders in workers.

RESULTSA total of 6260 workers completed the survey; their mean age was 31.1 ± 8.6 years, and 53.2% of them were males. The multilevel logistic regression analysis showed that after adjustment for sociodemographic factors such as age, sex, and martial status, more depressive disorders were reported in the enterprises with higher score of "production safety training" than in those with lower score (OR = 1.46, 95%CI = 1.07 ∼ 1.97); fewer depressive disorders were reported in the enterprises with higher score of "colleagues concerned about production safety" than in those with lower score (OR = 0.08, 95%CI = 0.03 ∼ 0.26); the relationships of "safety warnings and precautions" and "managers concerned about production safety" with workers' depressive disorders were not statistically significant (OR = 0.78, 95%CI = 0.48 ∼ 1.28; OR = 1.08, 95%CI = 0.68 ∼ 1.72).

CONCLUSIONDepressive disorders in manufacturing workers are related to the safety climate at workplace, which indicates that a good safety climate at workplace should be created to prevent and control depressive disorders in workers.

Adolescent ; Adult ; China ; Depression ; Female ; Humans ; Logistic Models ; Male ; Middle Aged ; Occupational Health ; Safety ; Surveys and Questionnaires ; Workplace ; Young Adult

Objective： The aim of this study was to investigate the efficacy and toxicity of single agent topotecan(second line) or topotecan＋ cisplatin (first line) in the treatment of the patients with small cell lung cancer (SCLC). Methods： Ninety-seven patients were evaluated efficacy and toxicity in 100 eligible patients in a multiple center clinical trail. Topotecan was administrated as a second line single agent in 38 relapse SCLC patients and the dose of topotecan was 1.25 mg· （ m2· d） -1 for 5 days and repeat every 3 weeks. Topotecan＋ cisplatin regimen was used in the chemonaive SCLC patients and the dose of topotecan was reduced to 1 mg· （ m2· d） -1 for 5 days and the cisplatin was 80 mg· （ m2· d） -1 for one dose. Results： The response rate was 37.5％ as second line chemotherapy in relapse SCLC, including complete response of 3.1％ and the partial response 34.4. The response rate was 79.6％ (complete response,22.4％ and partial response,57.1％ ) when cisplatin was combined with topotecan in the chemonaive SCLC patients. Bone marrow suppression was the main toxicity of topotecan and Grade Ⅲ -Ⅳ neutropenia and thrombopenia was observed in 39.9％ and 31.6％ respectively in single agent regimen and 61.0％ and 39.9％ in combined regimen respectively. The non-hemotological toxicity was mineral. Conclusion： Topotecan may be an effective drugs for the patients with SCLC when used as the first or the second line regimen, and more efficacy when combine with cisplatin. The main toxicity of topotecan is hemotological toxicity.

BACKGROUND: Perioperative treatment has become an increasingly important aspect of the management of patients with non-small cell lung cancer (NSCLC). Small-scale clinical studies performed in recent years have shown improvements in the major pathological remission rate after neoadjuvant therapy, suggesting that it will soon become an important part of NSCLC treatment. Nevertheless, neoadjuvant immunotherapy may be accompanied by serious adverse reactions that lead to delay or cancelation of surgery, additional illness, and even death, and have therefore attracted much attention. The purpose of the clinical recommendations is to form a diagnosis and treatment plan suitable for the current domestic medical situation for the immune-related adverse event (irAE). METHODS: This recommendation is composed of experts in thoracic surgery, oncologists, thoracic medicine and irAE related departments (gastroenterology, respirology, cardiology, infectious medicine, hematology, endocrinology, rheumatology, neurology, dermatology, emergency section) to jointly complete the formulation. Experts make full reference to the irAE guidelines, large-scale clinical research data published by thoracic surgery, and the clinical experience of domestic doctors and publicly published cases, and repeated discussions in multiple disciplines to form this recommendation for perioperative irAE. RESULTS: This clinical recommendation covers the whole process of prevention, evaluation, examination, treatment and monitoring related to irAE, so as to guide the clinical work comprehensively and effectively. CONCLUSIONS Perioperative irAE management is an important part of immune perioperative treatment of lung cancer. With the continuous development of immune perioperative treatment, more research is needed in the future to optimize the diagnosis and treatment of perioperative irAE.